≡ Risteys
R9

Documentation Changelog GitHub Contact & Feedback

Reactive arthropathies

DOID EFO MESH SNOMED PheWeb

M13_REACTARTH

reactive arthritis: Reactive arthritis (ReA) is an autoimmune disorder belonging to the group of seronegative spondyloarthropathies and is characterized by the classic triad of arthritis, urethritis and conjunctivitis.

Endpoint definition

↥
FinnGen phenotype data

392423 individuals

diagram downward connector

Apply sex-specific rule None

392423

diagram downward connector

Check conditions None

392423

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 M02, M03*
Hospital discharge: ICD-9 7111|7115|7118|713
Hospital discharge: ICD-8 71490
Cause of death: ICD-10 M02, M03*
Cause of death: ICD-9 7111|7115|7118|713
Cause of death: ICD-8 71490

2 out of 7 registries used, show all original rules.

2886

diagram downward connector

Check minimum number of events None

2886

diagram downward connector

Include endpoints None

2886

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

2813

diagram downward connector
M13_REACTARTH

Control definitions

Control exclude M13_ARTHROPATHIES

Extra metadata

Level in the ICD hierarchy 3
First used in FinnGen datafreeze DF2

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 2813 1553 1260
Unadjusted prevalence (%) 0.75 0.74 0.76
Mean age at first event (years) 43.80 41.99 46.03

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.01 0.84 [0.28, 2.57] 7.7e-1 214
15 years 0.00 0.72 [0.28, 1.83] 4.9e-1 94
5 years 0.00 1.57 [0.71, 3.44] 2.6e-1 47
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: M13_REACTARTH – Reactive arthropathies
GWS hits:

Survival analyses between endpoints

↥

Plot

before Reactive arthropathies
after Reactive arthropathies

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Reactive arthropathies

↥

Endpoint not on priority list, no data to show.